Document Type
Article
Date of Original Version
2021
Department
Biomedical and Pharmaceutical Sciences
Abstract
Nanomedicines have shown great potential in cancer therapy; in particular, the combination of chemotherapy and immunotherapy (namely chemoimmunotherapy) that is revolutionizing cancer treatment. Currently, most nanomedicines for chemoimmunotherapy are still in preclinical and clinical trials. Lipid-based nanoparticles, the most widely used nanomedicine platform in cancer therapy, is a promising delivery platform for chemoimmunotherapy. In this review, we introduce the commonly used immunotherapy agents and discuss the opportunities for chemoimmunotherapy mediated by lipid-based nanoparticles. We summarize the clinical trials involving lipid-based nanoparticles for chemoimmunotherapy. We also highlight different chemoimmunotherapy strategies based on lipid-based nanoparticles such as liposomes, nanodiscs, and lipid-based hybrid nanoparticles in preclinical research. Finally, we discuss the challenges that have hindered the clinical translation of lipid-based nanoparticles for chemoimmunotherapy, and their future perspectives.
Citation/Publisher Attribution
Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021). Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics, 13(4), 520. doi:10.3390/pharmaceutics13040520
Available at: https://doi.org/10.3390/pharmaceutics13040520
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
- Citations
- Citation Indexes: 35
- Usage
- Downloads: 192
- Abstract Views: 21
- Captures
- Readers: 73
- Mentions
- Blog Mentions: 1
